Literature DB >> 24894944

EGFR exon 19 deletion mutations and systemic/central nervous system miliary metastasis: clinical correlations and response to therapy.

Seerat Poonia1, Eamon M Berge2, Dara L Aisner3, Denise Damek2, Robert C Doebele4.   

Abstract

Entities:  

Keywords:  EGFR; Erlotinib; Leptomeningeal; Miliary nodules; Non–small-cell lung cancer

Mesh：

Substances：

Year:  2014        PMID： 24894944      PMCID： PMC4160348          DOI： 10.1016/j.cllc.2014.04.005

Source DB:  PubMed          Journal:  Clin Lung Cancer        ISSN： 1525-7304            Impact factor:   4.785


× No keyword cloud information.
  14 in total

1.  Carcinomatous meningitis in non-small-cell lung cancer: response to high-dose erlotinib.

Authors:  Nirav Dhruva; Mark A Socinski
Journal:  J Clin Oncol       Date:  2009-06-01       Impact factor: 44.544

2.  High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer.

Authors:  Jennifer L Clarke; William Pao; Nian Wu; Vincent A Miller; Andrew B Lassman
Journal:  J Neurooncol       Date:  2010-02-10       Impact factor: 4.130

3.  Miliary never-smoking adenocarcinoma of the lung: strong association with epidermal growth factor receptor exon 19 deletion.

Authors:  Eckart Laack; Ronald Simon; Marc Regier; Birte Andritzky; Pierre Tennstedt; Christian Habermann; Christoph Zur Verth; Ina Thöm; Tobias Grob; Guido Sauter; Carsten Bokemeyer
Journal:  J Thorac Oncol       Date:  2011-01       Impact factor: 15.609

4.  Association of diffuse, random pulmonary metastases, including miliary metastases, with epidermal growth factor receptor mutations in lung adenocarcinoma.

Authors:  Yosuke Togashi; Katsuhiro Masago; Takeshi Kubo; Yuichi Sakamori; Young Hak Kim; Yukimasa Hatachi; Akiko Fukuhara; Tadashi Mio; Kaori Togashi; Michiaki Mishima
Journal:  Cancer       Date:  2010-09-30       Impact factor: 6.860

5.  Clinical outcome in patients with leptomeningeal metastasis from non-small cell lung cancer: Okayama Lung Cancer Study Group.

Authors:  Shigeki Umemura; Kazuya Tsubouchi; Hiroshige Yoshioka; Katsuyuki Hotta; Nagio Takigawa; Keiichi Fujiwara; Naokatsu Horita; Yoshihiko Segawa; Noboru Hamada; Ichiro Takata; Hiromichi Yamane; Haruhito Kamei; Katsuyuki Kiura; Mitsune Tanimoto
Journal:  Lung Cancer       Date:  2012-04-07       Impact factor: 5.705

6.  Functional analysis of epidermal growth factor receptor (EGFR) mutations and potential implications for EGFR targeted therapy.

Authors:  Rama Krishna Kancha; Nikolas von Bubnoff; Christian Peschel; Justus Duyster
Journal:  Clin Cancer Res       Date:  2009-01-15       Impact factor: 12.531

7.  Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.

Authors:  Tony S Mok; Yi-Long Wu; Sumitra Thongprasert; Chih-Hsin Yang; Da-Tong Chu; Nagahiro Saijo; Patrapim Sunpaweravong; Baohui Han; Benjamin Margono; Yukito Ichinose; Yutaka Nishiwaki; Yuichiro Ohe; Jin-Ji Yang; Busyamas Chewaskulyong; Haiyi Jiang; Emma L Duffield; Claire L Watkins; Alison A Armour; Masahiro Fukuoka
Journal:  N Engl J Med       Date:  2009-08-19       Impact factor: 91.245

8.  Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

Authors:  Lecia V Sequist; James Chih-Hsin Yang; Nobuyuki Yamamoto; Kenneth O'Byrne; Vera Hirsh; Tony Mok; Sarayut Lucien Geater; Sergey Orlov; Chun-Ming Tsai; Michael Boyer; Wu-Chou Su; Jaafar Bennouna; Terufumi Kato; Vera Gorbunova; Ki Hyeong Lee; Riyaz Shah; Dan Massey; Victoria Zazulina; Mehdi Shahidi; Martin Schuler
Journal:  J Clin Oncol       Date:  2013-07-01       Impact factor: 44.544

9.  Metastatic brain tumors from non-small cell lung cancer with EGFR mutations: distinguishing influence of exon 19 deletion on radiographic features.

Authors:  Akimasa Sekine; Terufumi Kato; Eri Hagiwara; Takeshi Shinohara; Takanobu Komagata; Tae Iwasawa; Hiroaki Satoh; Katsumi Tamura; Tomotaka Kasamatsu; Kenji Hayashihara; Takefumi Saito; Hiroshi Takahashi; Takashi Ogura
Journal:  Lung Cancer       Date:  2012-02-13       Impact factor: 5.705

Review 10.  Successful erlotinib rechallenge for leptomeningeal metastases of lung adenocarcinoma after erlotinib-induced interstitial lung disease: a case report and review of the literature.

Authors:  Yosuke Togashi; Katsuhiro Masago; Yasuhiro Hamatani; Yuichi Sakamori; Hiroki Nagai; Young Hak Kim; Michiaki Mishima
Journal:  Lung Cancer       Date:  2012-05-12       Impact factor: 5.705
View more
  4 in total

1.  Clinicopathologic Characteristics, Treatment Outcomes, and Acquired Resistance Patterns of Atypical EGFR Mutations and HER2 Alterations in Stage IV Non-Small-Cell Lung Cancer.

Authors:  Tejas Patil; Rao Mushtaq; Sydney Marsh; Christine Azelby; Miheer Pujara; Kurtis D Davies; Dara L Aisner; William T Purcell; Erin L Schenk; Jose M Pacheco; Paul A Bunn; D Ross Camidge; Robert C Doebele
Journal:  Clin Lung Cancer       Date:  2019-11-21       Impact factor: 4.785

2.  Patterns of spread and prognostic implications of lung cancer metastasis in an era of driver mutations.

Authors:  F Hsu; A De Caluwe; D Anderson; A Nichol; T Toriumi; C Ho
Journal:  Curr Oncol       Date:  2017-08-31       Impact factor: 3.677

3.  Imaging Pattern of Diffuse Intrapulmonary Metastases in Lung Cancer Was Associated with Poor Prognosis to Epidermal Growth Factor Receptor Inhibitors.

Authors:  Yang Fu; Yuan Tang; Yue Zheng; Yue-Yun Chen; Ye Hong; Pei-Pei Wang; Qing Li; Ting Liu; Zhen-Yu Ding
Journal:  Cancer Manag Res       Date:  2020-11-17       Impact factor: 3.989

Review 4.  [Lung Adenocarcinomas with Pulmonary Miliary Metastases: A Case Report and Literature Review].

Authors:  Linxue Li; Liang Zhou; Jianyong Zhang
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2019-12-20
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.